MINIject Global Long-Term Follow-up Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Minimally invasive glaucoma surgery (MIGS): MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.

Study summary

The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.

Eligibility

Primary outcome measure(s)

• Proportion of patients with serious device-related adverse event in study eye — 5 years post-implantation
  The proportion of patients with at least one serious ocular adverse event in the study eye, related to the device, occurring between 2 and 5 years after the MINIject implantation.

Trial sites (9)